CSLLY 68.62 ▲ 0.91% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    CSL Limited

    OTC: CSLLY · Real-Time Price · USD
    68.62
    0.62 (0.91%)
    At close: Oct 03, 2025, 3:58 PM
    68.65
    0.04%
    After-hours: Oct 03, 2025, 03:41 PM EDT
    0.91%
    Bid 68.59
    Market Cap 132.86B
    Revenue (ttm) 15.47B
    Net Income (ttm) 3.04B
    EPS (ttm) 3.08
    PE Ratio (ttm) 22.28
    Forward PE 12.13
    Analyst n/a
    Dividends $2.14
    Ask 68.71
    Volume 5,354
    Avg. Volume (20D) 113,153
    Open 68.75
    Previous Close 68.00
    Day's Range 68.57 - 69.59
    52-Week Range 61.06 - 101.44
    Beta 0.26
    Ex-Dividend Date Sep 10, 2025

    About CSLLY

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol CSLLY
    Website n/a
    Full Company Profile
    news image

    1 week ago · businesswire.com

    CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

    SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)---- $TVTX #igan--CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guideline...

    news image

    1 month ago · seekingalpha.com

    CSL Limited (CSLLY) Q4 2025 Earnings Call Transcript

    CSL Limited (OTCQX:CSLLY) Q4 2025 Earnings Conference Call August 18, 2025 8:00 PM ET Company Participants Andy Schmeltz - Executive Vice President of CSL Behring Chris Cooper - Head of Investor Relat...

    news image

    1 month ago · reuters.com

    Australian biopharma firm CSL posts 14% rise in annual profit

    Australian biopharmaceutical company CSL reported 14% rise in annual earnings on Tuesday, driven by strong performance at its blood plasma business CSL Behring.

    2 months ago · youtube.com

    Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

    Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

    2 months ago · youtube.com

    President Trump demands drugmakers slash prices within 60 days

    CNBC's Joe Kernen reports on the latest news.

    Add to Watchlist